Cas:20717-86-6 Chlorotriisopropoxytitanium manufacturer & supplier

Chemical Name:Chlorotriisopropoxytitanium

CAS.NO:20717-86-6

Synonyms:Titanium(IV) chloride triisopropoxide;DICHLORODICYCLOPENTADIENYLTITANIUM;CHLOROTITANIUM TRIISOPROPOXIDE;Chlorotriisopropoxytitanium(IV);Chlorotitanium(IV) triisopropoxide;Dicyclopentadienyldichlorotitanium;Titanocene dichlorid;Titanium(4+) chloride 2-propanolate (1:1:3);Chlorotriisopropoxytitanium;Titanium, chlorotris(2-propanolato)-;Titanium chloride triisopropoxide;Dichlorotitanocene;MFCD00009861;titaniumferrocene

Molecular Formula:C₉H₂₁ClO₃Ti

Molecular Weight:260.581

HS Code:

Physical and Chemical Properties:

Melting point:35-40 °C

Boiling point:63-66°C 0,1mm

Density:1.091 g/mL at 25 °C(lit.)

Index of Refraction:

PSA:27.69000

Exact Mass:260.065857

LogP:3.31660

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2924 3/PG 2

Packing Group:II

Contact us for information like Titanium(IV) chloride triisopropoxide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,titaniumferrocene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Chlorotriisopropoxytitanium Use and application,Dichlorotitanocene technical grade,usp/ep/jp grade.

Related News: Speaking to Sky News, Raab said he could not confirm the ��precise number�� of those arriving into the UK on Sunday. Chlorotriisopropoxytitanium manufacturer There were no cases of hospitalization or death among people who received the vaccine, the company reported. Side effects were mild — fatigue, headaches and muscle pain — and reactions tended to be less frequent than those triggered by some already authorized vaccines, the company said. Chlorotriisopropoxytitanium supplier Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. Chlorotriisopropoxytitanium vendor A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. Chlorotriisopropoxytitanium factory There were no cases of hospitalization or death among people who received the vaccine, the company reported. Side effects were mild — fatigue, headaches and muscle pain — and reactions tended to be less frequent than those triggered by some already authorized vaccines, the company said.